Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Proqr Therapeutics (PRQR)

Proqr Therapeutics (PRQR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Proqr Therapeutics ZERNIKEDREEF 9 LEIDEN P7 2333 CK NLD

www.proqr.com Employees: 156 P: 31-88-166-7000

Description:

ProQR Therapeutics B.V. is a biotech company. It is engaged in the discovery and development of RNA-based therapeutics for the treatment of severe genetic disorders, with an initial focus on Cystic Fibrosis (CF). The Company's lead product candidate includes QR-010, a RNA-based oligonucleotide for the treatment of cystic fibrosis. ProQR Therapeutics B.V. is headquartered in Leiden, the Netherlands.

Key Statistics

Overview:

Market Capitalization, $K 299,766
Enterprise Value, $K 175,706
Shares Outstanding, K 81,680
Annual Sales, $ 7,050 K
Annual Net Income, $ -30,430 K
Last Quarter Sales, $ 4,230 K
Last Quarter Net Income, $ -8,920 K
EBIT, $ -28,980 K
EBITDA, $ -26,260 K
60-Month Beta 0.26
% of Insider Shareholders 8.40%
% of Institutional Shareholders 32.65%
Float, K 74,819
% Float 91.60%
Short Volume Ratio 0.23

Growth:

1-Year Return 154.93%
3-Year Return -48.96%
5-Year Return -57.03%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth 70.54%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.11 on 11/07/24
Next Earnings Date 11/12/24
Earnings Per Share ttm -0.32
EPS Growth vs. Prev Qtr -266.67%
EPS Growth vs. Prev Year -37.50%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

PRQR Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -71.58%
Return-on-Assets % -19.71%
Profit Margin % -431.63%
Debt/Equity 0.18
Price/Sales 41.71
Price/Cash Flow N/A
Price/Book 10.70
Book Value/Share 0.34
Interest Coverage -18.05
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar